Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
Full story
Read the full story at CNBC ↗
Continue reading this story on CNBC, the publisher that reported it.
AI tools
Written by AI from the article text. It can make mistakes; check the original story.
